Fropofol prevents disease progression in mice with hypertrophic cardiomyopathy
- PMID: 31424496
- PMCID: PMC8453292
- DOI: 10.1093/cvr/cvz218
Fropofol prevents disease progression in mice with hypertrophic cardiomyopathy
Abstract
Aims: Increased myofilament contractility is recognized as a crucial factor in the pathogenesis of hypertrophic cardiomyopathy (HCM). Direct myofilament desensitization might be beneficial in preventing HCM disease progression. Here, we tested whether the small molecule fropofol prevents HCM phenotype expression and disease progression by directly depressing myofilament force development.
Methods and results: Force, intracellular Ca2+, and steady-state activation were determined in isolated trabecular muscles from wild-type (WT) and transgenic HCM mice with heterozygous human α-myosin heavy chain R403Q mutation (αMHC 403/+). αMHC 403/+ HCM mice were treated continuously with fropofol by intraperitoneal infusion for 12 weeks. Heart tissue was analysed with histology and real-time PCR of prohypertrophic and profibrotic genes. Fropofol decreased force in a concentration-dependent manner without significantly altering [Ca2+]i in isolated muscles from both WT and αMHC 403/+ HCM mouse hearts. Fropofol also depressed maximal Ca2+-activated force and increased the [Ca2+]i required for 50% activation during steady-state activation. In whole-animal studies, chronic intra-abdominal administration of fropofol prevented hypertrophy development and diastolic dysfunction. Chronic fropofol treatment also led to attenuation of prohypertrophic and profibrotic gene expression, reductions in cell size, and decreases in tissue fibrosis.
Conclusions: Direct inhibition of myofilament contraction by fropofol prevents HCM disease phenotypic expression and progression, suggesting that increased myofilament contractile force is the primary trigger for hypertrophy development and HCM disease progression.
Keywords: Calcium; Fropofol; Hypertrophic cardiomyopathy; Myofilament.
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8453292/bin/cardiovascres_116_6_1175_f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8453292/bin/cardiovascres_116_6_1175_f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8453292/bin/cardiovascres_116_6_1175_f3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8453292/bin/cardiovascres_116_6_1175_f4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8453292/bin/cardiovascres_116_6_1175_f5.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8453292/bin/cardiovascres_116_6_1175_f6.gif)
Similar articles
-
Myofilament mechanical performance is enhanced by R403Q myosin in mouse myocardium independent of sex.Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1939-47. doi: 10.1152/ajpheart.00644.2007. Epub 2008 Feb 15. Am J Physiol Heart Circ Physiol. 2008. PMID: 18281382
-
Fropofol decreases force development in cardiac muscle.FASEB J. 2018 Aug;32(8):4203-4213. doi: 10.1096/fj.201701442R. Epub 2018 Mar 9. FASEB J. 2018. PMID: 29522375 Free PMC article.
-
Blocking cardiac growth in hypertrophic cardiomyopathy induces cardiac dysfunction and decreased survival only in males.Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H838-45. doi: 10.1152/ajpheart.00615.2006. Epub 2006 Sep 29. Am J Physiol Heart Circ Physiol. 2007. PMID: 17012357
-
Mutation-specific pathology and treatment of hypertrophic cardiomyopathy in patients, mouse models and human engineered heart tissue.Biochim Biophys Acta Mol Basis Dis. 2020 Aug 1;1866(8):165774. doi: 10.1016/j.bbadis.2020.165774. Epub 2020 Mar 23. Biochim Biophys Acta Mol Basis Dis. 2020. PMID: 32217077 Review.
-
Altered force generation and cell-to-cell contractile imbalance in hypertrophic cardiomyopathy.Pflugers Arch. 2019 May;471(5):719-733. doi: 10.1007/s00424-019-02260-9. Epub 2019 Feb 11. Pflugers Arch. 2019. PMID: 30740621 Free PMC article. Review.
Cited by
-
Human Resistin Induces Cardiac Dysfunction in Pulmonary Hypertension.J Am Heart Assoc. 2023 Mar 21;12(6):e027621. doi: 10.1161/JAHA.122.027621. Epub 2023 Mar 16. J Am Heart Assoc. 2023. PMID: 36927008 Free PMC article.
-
Ciprofol attenuates the isoproterenol-induced oxidative damage, inflammatory response and cardiomyocyte apoptosis.Front Pharmacol. 2022 Nov 22;13:1037151. doi: 10.3389/fphar.2022.1037151. eCollection 2022. Front Pharmacol. 2022. PMID: 36483733 Free PMC article.
-
lncRNA ADAMTS9-AS1/circFN1 Competitively Binds to miR-206 to Elevate the Expression of ACTB, Thus Inducing Hypertrophic Cardiomyopathy.Oxid Med Cell Longev. 2022 Mar 31;2022:1450610. doi: 10.1155/2022/1450610. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 35401927 Free PMC article.
-
Cardiomyopathies in China: A 2018-2019 state-of-the-art review.Chronic Dis Transl Med. 2020 Jul 5;6(4):224-238. doi: 10.1016/j.cdtm.2020.05.006. eCollection 2020 Dec. Chronic Dis Transl Med. 2020. PMID: 33336168 Free PMC article. Review.
References
-
- Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 2015;65:1249–1254. - PubMed
-
- Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med 2018;379:655–668. - PubMed
-
- Elliott K, Watkins H, Redwood CS. Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy. J Biol Chem 2000;275:22069–22074. - PubMed
-
- Yanaga F, Morimoto S, Ohtsuki I. Ca2+ sensitization and potentiation of the maximum level of myofibrillar ATPase activity caused by mutations of troponin T found in familial hypertrophic cardiomyopathy. J Biol Chem 1999;274:8806–8812. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous